IRCT20190129042541N1尚未招募3 期
investigate efficacy of fibrinogen blood level correction between 1.5 - 2 gr/lit to above 2 gr/lit with bleeding rate during operation and post operation hospital course in traumatic brain injury
vice chancellor of research . shiraz university of medical sciences0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 16 years 至 65 years（—）
- 性别
- All
入选标准
- •patients who are older than sixteen years and brought to Emtiaz hospital ER, affiliated to Shiraz Univercity of medical sciemces,Shiraz, Iran, between March 2019 to March 2020 and underwent skull craniotomy whom fibrinogen level is between 1.5 to 2.0 gr/lit are include in our study
排除标准
- •patients who have coagulopathy in lab data such as abnormal PTwe exclude the patients who have coagulopathy in lab data such as abnormal PT,PTT,INR, platelets counts or history of coagulopathy disorders or underwent another major surgery from other services in this admission before skull craniotomy surgery from our study
研究者
相似试验
已完成
不适用
Serum fibrinogen and fibrin degradation products (FDP) changes in hypothermia and normothermia in patients undergoing bypasscoronary heart disease.Atherosclerotic heart disease of native coronary arteryIRCT20180930041189N1Shiraz University of Medical Sciences80
进行中（未招募）
不适用
Efficacy and safety of Fibrinogen Concentrate (Human) for on-demand treatment of acute bleeding in subjects with congenital fibrinogen deficiency - NDCongenital fibrinogen deficiency ( afibrinogenemia, severe hypofibrinogenemia)MedDRA version: 9.1Level: LLTClassification code 10016075EUCTR2007-004088-22-ITCSL BEHRING GmbH23
进行中（未招募）
不适用
Efficacy and safety of Fibrinogen Concentrate (Human) for on-demand treatment of acute bleeding in subjects with congenital fibrinogen deficiencyFibrinogen Concentrate (Human) (FCH) - efficacy and safetyCongenital fibrinogen deficiency (afibrinogenemia, severe hypofibrinogenemia)MedDRA version: 12.0Level: LLTClassification code 10016075Term: Factor I deficiencyEUCTR2007-004088-22-DECSL Behring GmbH23
进行中（未招募）
1 期
se of fibrinogen in the treatment of bleeding in thrombopenic patients after intensive chemotherapy refractory to platelet transfusio- Major patient- Patient with malignant hemopathy requiring intensive chemotherapy, autologous or allogeneic hematopoietic stem cell transplantation- Grade = 1 hemorrhagic symptom according to WHO - WHO classification- Body weight between 38 and 78 kg- Patient presenting with a platelet refractory state defined according to the Corrected Count Increment (CCI)- Patient affiliated to a social security schemeMedDRA version: 21.1Level: LLTClassification code 10066481Term: Hematological malignancySystem Organ Class: 100000004864EUCTR2021-000990-10-FRInstitut de Cancérologie Lucien Neuwirth10
已完成
3 期
The Fibrin Pad Liver StudyHemorrhageNCT01166243Ethicon, Inc.84